Trigeminal Neuralgia - Drug Pipeline Landscape, 2023

Trigeminal Neuralgia - Drug Pipeline Landscape, 2023

Trigeminal Neuralgia (TN), also known as tic douloureux, is a condition that causes painful sensations similar to an electric shock on one side of the face. The pain typically involves the lower face and jaw, although sometimes it affects the area around the nose and above the eye.

There are two types of TN primary and secondary. Primary trigeminal Neuralgia has been linked to the compression of the nerve. Trigeminal Neuralgia is caused by a blood vessel exerting pressure on the nerve near your brain stem. This condition can also be caused by a tumor or lesion that compresses nerves. Other known causes a swollen blood vessel or tumor that puts pressure on the nerve and multiple sclerosis.

Diagnosis of Trigeminal Neuralgia will depend on the type and location of the pain an. Doctor will first evaluate medical history and perform a physical exam. A neurological examination and magnetic resonance imaging (MRI) can also be suggested for diagnosis.

Treatment of Trigeminal Neuralgia includes medications like anticonvulsant drugs, tricyclic antidepressants and muscle relaxants. Surgical procedures like balloon compression and glycerol injection rhizotomy can be used for the treatment.

Companies active in the development of trigeminal neuralgia drugs include Amgen Inc., Biogen, Noema Pharma AG and Biohaven Pharmaceuticals, Inc.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Trigeminal Neuralgia treatment such as Basimglurant, BIIB074, Rimegepant and others. Key players involved in the development of therapies to treat Trigeminal Neuralgia are Biogen, Biohaven Pharmaceuticals, Inc, Coda Biotherapeutics Inc, Initiator Pharma AS, Noema Pharma AG and others. One drug is under late-stage Phase III clinical trials and two drugs are in Phase II clinical trials and some other drugs are under Phase I, Preclinical and Discovery stages of development.

In October 2022, Noema Pharma received FDA Fast Track designation to its mGluR5 inhibitor basimglurant (NOE-101) for the treatment of trigeminal neuralgia (TN).

Report Highlights

Global Insight Service's, Trigeminal Neuralgia - Drug Pipeline Landscape, 2023 report provides an overview of the Trigeminal Neuralgia pipeline drugs. This report covers detailed insights on Trigeminal Neuralgia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Trigeminal Neuralgia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.